{"nctId":"NCT00083174","briefTitle":"Exemestane in Preventing Cancer in Postmenopausal Women at Increased Risk of Developing Breast Cancer","startDateStruct":{"date":"2004-12-03","type":"ACTUAL"},"conditions":["Breast Cancer"],"count":4560,"armGroups":[{"label":"Exemestane","type":"OTHER","interventionNames":["Drug: exemestane"]}],"interventions":[{"name":"exemestane","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"* At increased risk of developing breast cancer, due to at least one of the following risk factors:\n\n  * Gail score ≥ 1.66\n  * Age ≥ 60 years\n  * Prior atypical ductal hyperplasia, lobular hyperplasia, or lobular carcinoma in situ on breast biopsy\n  * Prior ductal carcinoma in situ (DCIS) treated with total mastectomy with or without tamoxifen (tamoxifen must have been completed ≥ 3 months prior to randomization)\n* No prior DCIS treated with lumpectomy with or without radiation\n* No prior invasive breast cancer\n* Not BRCA1 or BRCA2 carriers\n\nPATIENT CHARACTERISTICS:\n\nPrevious:\n\n* 35 and over\n* Female\n* Postmenopausal, defined as one of the following:\n\n  * over 50 years of age with no spontaneous menses for at least 12 months before study entry\n  * 50 years of age or under with no menses (spontaneous or secondary to hysterectomy) for at least 12 months before study entry AND with follicle-stimulating hormone level within postmenopausal range\n  * Underwent prior bilateral oophorectomy\n* No other malignancies within the past 5 years except adequately treated nonmelanoma skin cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumors with no evidence of disease for ≥ 5 years\n* No uncontrolled hypothyroidism or hyperthyroidism\n* No major medical or psychiatric illness (including substance and alcohol abuse within the past 2 years) that would preclude study participation or compliance\n* Must be accessible for treatment and follow-up\n* Willing to complete quality of life questionnaires in either English or French\n\nCurrent: MAP.3 participants who were randomized to the exemestane arm, are currently receiving exemestane as part of the MAP.3 study and who have not completed 5 years of exemestane.\n\nOR MAP.3 study participants who were randomized to the placebo arm and who have either completed 5 years of study drug or who are still receiving placebo. Note: this applies only to centres that choose to allow placebo \"cross-over\".\n\nPRIOR CONCURRENT THERAPY:\n\nPrevious:\n\n* More than 3 months since prior and no concurrent hormone replacement therapies\n* More than 3 months since systemic estrogenic, androgenic, or progestational agents\n* More than 3 months since prior and no concurrent hormonal therapies, including, but not limited to the following:\n\n  * Luteinizing-hormone releasing-hormone analogs (e.g., goserelin or leuprolide)\n  * Progestogens (e.g., megestrol)\n  * Prolactin inhibitors (e.g., bromocriptine)\n  * Antiandrogens (e.g., cyproterone acetate)\n  * Selective estrogen-receptor modulators (e.g., tamoxifen, toremifene, or raloxifene)\n* No investigational drug within 30 days or 5 half lives prior to randomization\n* No concurrent endocrine therapy\n* No concurrent estrogens, androgens, or progesterones\n* Concurrent low dose (≤ 100 mg/day) prophylactic aspirin allowed\n* Concurrent bisphosphonates for prevention or treatment of osteoporosis allowed\n* No other concurrent medications that may have an effect on study endpoints\n\nCurrent: There are no prior concurrent therapy restrictions for the amended MAP.3 study.","healthyVolunteers":true,"sex":"FEMALE","minimumAge":"35 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Women With Serious Adverse Events","description":"Percentage of serious adverse events for women who choose to receive 5 years of exemestane as preventative therapy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null}]}]}]},{"type":"PRIMARY","title":"Invasive Breast Cancer Incidence (Breast Cancer-Free Survival)","description":"Invasive breast cancer incidence was estimated from the breast cancer-free survival (BCFS) which was calculated for all women from the day of the randomization to the earliest date of diagnosis for invasive breast cancer. Women who died from other causes were censored at the time of death. If a woman did not develop an invasive breast cancer, or died, BCFS was censored on the date of the last day the woman was known alive (LKA), which was the latest of the date of assessment. Women who had breast cancer before study entry were also censored at the time of randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":null},{"groupId":"OG001","value":"0.55","spread":null}]}]}]},{"type":"SECONDARY","title":"Total Incidence of Invasive and Non-invasive (DCIS) Breast Cancer","description":"It was estimated from the Total Breast Cancer-Free Survival (TBCFS), which was calculated for women who developed invasive or non-invasive (DCIS) breast cancer as the time from the date of randomization to the earliest date of diagnosis for invasive or non-invasive (DCIS) breast cancer. Women who died from other causes were censored at the time of death. Women who had breast cancer before entry were censored at the time of randomization. If a woman did not develop an invasive or non-invasive (DCIS) breast cancer, or died, TBCFS will be censored on the date of last known alive.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.35","spread":null},{"groupId":"OG001","value":"0.77","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Lobular Carcinoma in Situ, Atypical Ductal Hyperplasia and Atypical Lobular Hyperplasia Events","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.07","spread":null},{"groupId":"OG001","value":"0.20","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Clinical Breast Biopsies","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of All Clinical Fractures","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"149","spread":null},{"groupId":"OG001","value":"143","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Clinically Relevant Cardiac Events","description":"Events including myocardial infarctions and angina requiring percutaneous transluminal coronary angioplasty or coronary artery bypass graft, fatal and nonfatal strokes and all vascular deaths","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"111","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidences of Other Malignancies","description":"Other malignancies includes any other malignancy which is not in breast.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":39,"n":2240},"commonTop":["hot flashes","Pain Joint","fatigue","sweating","hypertension"]}}}